Analysts Set Pfizer Inc. (NYSE:PFE) PT at $28.19

Pfizer Inc. (NYSE:PFE) has received a consensus rating of “Hold” from the twenty-three analysts that are presently covering the company, MarketBeat reports. Three equities research analysts have rated the stock with a sell recommendation, thirteen have assigned a hold recommendation, six have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $28.1905.

A number of equities research analysts have recently commented on the stock. Barclays began coverage on shares of Pfizer in a report on Thursday, February 19th. They set an “underweight” rating and a $25.00 price target on the stock. UBS Group assumed coverage on shares of Pfizer in a report on Tuesday, January 6th. They issued a “neutral” rating and a $25.00 price objective for the company. Zacks Research upgraded Pfizer from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 24th. Bank of America decreased their price target on Pfizer from $29.00 to $28.00 and set a “neutral” rating for the company in a research note on Monday, December 15th. Finally, Wolfe Research set a $24.00 price objective on Pfizer and gave the company an “underperform” rating in a research report on Wednesday, December 17th.

Pfizer Price Performance

PFE opened at $28.08 on Friday. The firm has a market cap of $159.67 billion, a PE ratio of 20.65 and a beta of 0.47. The stock has a 50-day moving average price of $26.94 and a 200-day moving average price of $25.75. Pfizer has a 1 year low of $20.92 and a 1 year high of $28.31. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.57 by $0.09. The company had revenue of $17.56 billion for the quarter, compared to the consensus estimate of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. Pfizer’s revenue for the quarter was down 1.2% on a year-over-year basis. During the same period in the prior year, the firm posted $0.63 EPS. Sell-side analysts predict that Pfizer will post 2.95 earnings per share for the current fiscal year.

Institutional Trading of Pfizer

A number of institutional investors have recently made changes to their positions in PFE. Horizon Financial Services LLC lifted its holdings in shares of Pfizer by 174.8% during the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 645 shares during the period. Godfrey Financial Associates Inc. bought a new stake in shares of Pfizer in the fourth quarter worth $26,000. YANKCOM Partnership purchased a new stake in Pfizer during the fourth quarter valued at $28,000. HFM Investment Advisors LLC increased its position in Pfizer by 61.0% during the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 427 shares during the last quarter. Finally, Grey Fox Wealth Advisors LLC bought a new position in Pfizer in the third quarter valued at about $29,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Fresh real‑world data from Pfizer’s Swedish observational study on Ibrance (palbociclib) is being framed as a positive signal for the drug’s real‑world effectiveness and market durability, which could support oncology revenue expectations. Pfizer’s Swedish Ibrance Study
• Positive Sentiment: Heightened media and retail investor attention around Pfizer’s GLP‑1/weight‑loss pipeline (including coverage noting share strength despite a high‑profile “pass” comment) is boosting sentiment—investors are pricing potential upside from a once‑monthly treatment. Pfizer’s (PFE) Shares Up Since Jim Cramer Said “Pass”
• Positive Sentiment: Dividend appeal remains a tailwind for income investors—Pfizer is regularly cited among large caps with attractive dividends, supporting buy‑and‑hold interest. Pfizer – Among the 15 Large Cap Stocks with Highest Dividends
• Neutral Sentiment: Retail and institutional attention is elevated (high search/coverage), which can amplify moves but doesn’t guarantee direction — monitor whether flow sustains. Investors Heavily Search Pfizer Inc. (PFE)
• Neutral Sentiment: Broader sector moves (e.g., large deals and AI partnerships at peers) are reshaping investor rotation in healthcare but are not direct Pfizer catalysts; they do, however, affect relative valuation dynamics. Eli Lilly Ramps Up AI Ambitions
• Negative Sentiment: Fundamentals still carry risk: quarterly revenue was slightly down year‑over‑year even as EPS beat estimates, and Pfizer faces stiff competition in the GLP‑1/weight‑loss space from larger early movers—both could cap upside if execution or pricing weakens.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.